Novo Nordisk’s ‘There’s Only One Ozempic’ campaign is about reasserting the drugmaker’s brand name in an increasingly competitive landscape. Ozempic-maker Novo Nordisk turned to the

ABSTRACT Background GLP-1 receptor agonists (GLP-1) and dual GLP-1/gastric inhibitory polypeptide (GIP) agonists emerged in recent years to promote weight loss. By reducing subcutaneous fat,

ABSTRACT Introduction The global prevalence of obesity has continued to increase at alarming rates. More recently, there has been an exponential increase in the usage

Oprah Winfrey at the American Ballet Theatre Gala on October 22, 2025. Lanna Apisukh/WWD via Getty Images Oprah Winfrey has been a weight-loss icon for

Who says pharma can’t have personality? Ozempic leans into humor with a familiar duo, Justin Long and John Hodgman from the ‘Mac VS PC’ era.

Lupin Atlantis Holdings SA (LAHSA) has entered into a partnership with Galenicum for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist

Justin Long and John Hodgman this time represent, respectively, Novo Nordisk’s original GLP-1, Ozempic, vs. “other GLP-1 products for type 2 diabetes.”

What You Should Know – Vida Health has partnered with RxSaveCard to launch Vida Self-Pay, a first-of-its-kind platform that bypasses traditional PBM markups for anti-obesity

A new financial report claims weight loss drugs like Ozempic and Wegovy could deliver an unexpected beneficiary: the airline industry. According to a study from

WICHITA FALLS, Texas, Jan. 20, 2026 /PRNewswire/ — CoreAge Rx, a leading telehealth pharmacy specializing in personalized medication services, today announced a strategic New Year’s

Low energy. “Ozempic face.” Feeling like a deflated balloon. They can be the downsides for people on GLP-1s, the increasingly popular drugs that go by

Bariatric surgery beats GLP-1s for type 2 diabetes across income levels, study says  statnews.com Northwest Health Offers Seminar about Weight Loss Surgery and GLP-1a  greatnews.life Bariatric surgery

In a review of 258 patients with Type 2 diabetes who underwent metabolic bariatric surgery or medical and lifestyle interventions, including GLP-1 drugs, surgery was

Key Points Novo Nordisk just launched an oral version of its popular weight-loss therapy, Wegovy. This move might help it make some headway in an

Key Points Viking Therapeutics’ stock was volatile in 2025 due to clinical trial results. VK2735’s oral form faced safety concerns but remains promising. Viking could

Nearly 2.2 million patients were prescribed a GLP-1 RA between January 2019 and December 2025, according to the study.

30 Ways Trump Impacted The World In His First Year Authored by Travis Gillmore and Cathy He via The Epoch Times, President Donald Trump used

This study examines the prescribing of glucagon-like peptide-1 receptor agonists for adolescents with obesity and associated disparities.

This comparative effectiveness research study examines whether kidney outcomes differ with sodium-glucose cotransporter-2 (SGLT2) inhibitor vs glucagon-like peptide-1 (GLP-1) receptor agonist treatment in individuals with

People with type 2 diabetes taking glucagon-like peptide-1 (GLP-1) receptor agonists were more likely to develop chronic cough than people using other second-line medications, a

Novo Nordisk is worried about competition and wants to be seen as the cool kid… by using a 20-year-old ad format.

Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded

The drugmaker is reprising an Apple campaign with Justin Long and John Hodgman to highlight Ozempic’s FDA-approved uses Drugmaker Novo Nordisk is running ads that

Ozempic isn’t just slimming waistlines—it may be trimming jet fuel bills, too. A new analysis from financial firm Jefferies estimates that if GLP-1 weight loss

SAN FRANCISCO–(BUSINESS WIRE)–Vida Health today announced the launch of Vida Self-Pay (Powered by RxSaveCard) to help employers reduce prescription drug costs.

These medications “don’t magically fix weight loss”, he said

Coca-Cola chairman and CEO James Quincey joins ‘Squawk Box’ to discuss the state of the consumer, impact of tariffs, impact of GLP-1 drugs on the

It’s Tuesday, January 20. This is The Front Page, your daily window into the world of The Free Press—and our take on the world at

Dulaglutide, a long-acting GLP-1 receptor agonist, can suppress copeptin levels in individuals with euvolaemia, a secondary analysis of two clinical trials shows. Medscape News UK

Discontinuing the use of GLP-1 weight-loss medications triggers weight regain more than previously thought, a new study suggested. The research, which was published in The

Weight Watchers’ new CMO on the brand’s reinvention, GLP-1 direction and ChatGPT launch  Ad Age

ABSTRACT Background Pharmacotherapy offers a potential solution for individuals with overweight and obesity to decrease their body weight. However, there is limited knowledge of the

On 20 January 2025, Donald Trump returned to the White House for a second term. It’s been politically divisive and visually rich. 12 months on,

Post Content

Abstract Aim To quantify the relative importance of frequency of administration in basal insulin treatment preferences of people living with type 2 diabetes (T2D) in

As the GLP-1 trend expands, a ‘halo effect’ is developing. Consumers in families of GLP-1 users are increasingly eating GLP-1-friendly diets. Meanwhile, many non-GLP-1 users

Although incretin (GLP-1)-based drugs are highly successful for weight loss, there are some limitations to their use. A modified prolactin-releasing peptide, NN501, causes significant weight

Sebhat et al. present a strategy to mimic bariatric surgery by activating specialized intestinal cells that secrete satiety hormones, including GLP-1. Preclinically, a combination of

A new compass for the SKEPDOC column. This column was founded by Harriet Hall, MD (1945–2023) who wrote it from 2006 to 2023. In 2026,